SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

UBS Upgrades Ionis Pharmaceuticals to Neutral, Raises Price Target to $37.5

UBS analyst Esther Rajavelu upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Sell to Neutral and raises the price target from $33 to $37.5.

05/07/2021 10:42
UBS analyst Esther Rajavelu upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Sell to Neutral and raises the price target from $33 to $37.5.